SCHEMBL5013637

SCHEMBL5013637

CCCCN(C(=O)c1cc(NC(=O)c2cc(F)c(F)cc2Cl)[nH]n1)C1CCN(C(=O)C(=O)O)CC1

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
LMNA P02545 2/20 0.39
PTBP1 P26599 1/20 0.39
UBE2M P61081 8/20 0.38
DCUN1D1 Q96GG9 8/20 0.38
HTT P42858 1/20 0.38
RECQL P46063 1/20 0.38
KMT2A Q03164 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.36
HPGD P15428 1/20 0.36
NTRK1 P04629 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14587657 0.95 UBE2M (0.38) ALDH1A1LMNAUBE2MDCUN1D1HTT
SCHEMBL5013420 0.94 ALDH1A1 (0.38) ALDH1A1LMNAPTBP1UBE2MDCUN1D1
SCHEMBL14587654 0.93 ALDH1A1 (0.47) ALDH1A1LMNAPTBP1UBE2MDCUN1D1
SCHEMBL5013422 0.92 SMN1; SMN2 (0.40) ALDH1A1LMNAPTBP1UBE2MDCUN1D1
SCHEMBL5010446 0.88 MAPT (0.39) ALDH1A1LMNAPTBP1UBE2MDCUN1D1
SCHEMBL5009754 0.88 NPC1 (0.42) ALDH1A1UBE2MDCUN1D1HTTRECQL
SCHEMBL5008467 0.88 HTT (0.37) ALDH1A1LMNAPTBP1UBE2MDCUN1D1
SCHEMBL5010424 0.88 ENPP2 (0.42) ALDH1A1LMNAUBE2MDCUN1D1HTT
SCHEMBL5008205 0.88 HTT (0.41) ALDH1A1UBE2MDCUN1D1HTTRECQL
SCHEMBL14587658 0.87 ALDH1A1 (0.36) ALDH1A1LMNAUBE2MDCUN1D1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL ALDH1A1 1278/4885LMNA 2123/4885PTBP1 2885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.